NEWSROOM Stay current with MiRXES Newsroom > Media Releases MiRXES Secures US$77 Million Series C Funding to Accelerate Multi-Cancer Early Detection Pipeline with Overwhelming Investor Support SINGAPORE, 8 July 2021 – MiRXES Pte Ltd, a biotechnology company focused on improving and saving lives with RNA-powered disease early detection tests, announced today it has raised US$77 million …
Tested and Proven COVID-19 Testing Solutions MiRXES offers complete COVID-19 testing solutions, starting from sample collection and preservation, through easy and reliable RNA extraction, to tested and proven SARS-CoV-2 RT-PCR diagnostic tests and mutation panels for quick identification of key variants. Sample Collection & Processing Solutions Swab Collection System Collect, handle, and store nasal and …
Tested and Proven COVID-19 Testing Solutions MiRXES offers complete COVID-19 testing solutions, starting from sample collection and preservation, through easy and reliable RNA extraction, to tested and proven SARS-CoV-2 RT-PCR diagnostic tests and mutation panels for quick identification of key variants. Sample Collection & Processing Solutions Swab Collection System Collect, handle, and store nasal and …
